{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:04:42Z","timestamp":1792800282444,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["[grant number 81971291]"],"award-info":[{"award-number":["[grant number 81971291]"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Wenzhou Municipal Science and Technology Bureau of China","award":["[grant number ZY2022002]"],"award-info":[{"award-number":["[grant number ZY2022002]"]}],"id":[{"id":"https:\/\/ror.org\/02fr0s482","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Proced Online"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), original found in synthetic heroin, causes Parkinson\u2019s disease (PD) in human through its metabolite MPP\n                      <jats:sup>+<\/jats:sup>\n                      by inhibiting complex I of mitochondrial respiratory chain in dopaminergic neurons. This study explored whether yeast internal NADH-quinone oxidoreductase (NDI1) has therapeutic effects in MPTP- induced PD models by functionally compensating for the impaired complex I. MPP\n                      <jats:sup>+<\/jats:sup>\n                      -treated SH-SY5Y cells and MPTP-treated mice were used as the PD cell culture and mouse models respectively. The recombinant\n                      <jats:italic>NDI1<\/jats:italic>\n                      lentivirus was transduced into SH-SY5Y cells, or the recombinant\n                      <jats:italic>NDI1<\/jats:italic>\n                      adeno-associated virus (rAAV5-\n                      <jats:italic>NDI1<\/jats:italic>\n                      ) was injected into substantia nigra pars compacta (SNpc) of mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study in vitro showed NDI1 prevented MPP\n                      <jats:sup>+<\/jats:sup>\n                      -induced change in cell morphology and decreased cell viability, mitochondrial coupling efficiency, complex I-dependent oxygen consumption, and mitochondria-derived ATP. The study in vivo revealed that rAAV-\n                      <jats:italic>NDI1<\/jats:italic>\n                      injection significantly improved the motor ability and exploration behavior of MPTP-induced PD mice. Accordingly, NDI1 notably improved dopaminergic neuron survival, reduced the inflammatory response, and significantly increased the dopamine content in striatum and complex I activity in substantia nigra.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      NDI1 compensates for the defective complex I in MPP\n                      <jats:sup>+<\/jats:sup>\n                      \/MPTP-induced models, and vastly alleviates MPTP-induced toxic effect on dopaminergic neurons. Our study may provide a basis for gene therapy of sporadic PD with defective complex I caused by MPTP-like substance.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12575-024-00236-3","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T02:01:38Z","timestamp":1712628098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Targeting Mitochondrial Complex I Deficiency in MPP+\/MPTP-induced Parkinson\u2019s Disease Cell Culture and Mouse Models by Transducing Yeast NDI1 Gene"],"prefix":"10.1186","volume":"26","author":[{"given":"Hongzhi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyou","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hezhi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihua","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"issue":"1\u20132","key":"236_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.mito.2006.11.007","volume":"7","author":"CY Tzen","year":"2007","unstructured":"Tzen CY, Mau BL, Hsu HJ. Analysis of disease-associated ND4 mutations: how do we know which mutation is pathogenic? Mitochondrion. 2007;7(1\u20132):151\u20136.","journal-title":"Mitochondrion"},{"issue":"7","key":"236_CR2","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.bbabio.2016.02.012","volume":"1857","author":"RJ Rodenburg","year":"2016","unstructured":"Rodenburg RJ. Mitochondrial complex I-linked disease. Biochim Biophys Acta. 2016;1857(7):938\u201345.","journal-title":"Biochim Biophys Acta"},{"key":"236_CR3","doi-asserted-by":"publisher","first-page":"1023574","DOI":"10.3389\/fnagi.2022.1023574","volume":"14","author":"J Dulski","year":"2022","unstructured":"Dulski J, Uitti RJ, Ross OA, Wszolek ZK. Genetic architecture of Parkinson\u2019s disease subtypes - review of the literature. Front Aging Neurosci. 2022;14:1023574.","journal-title":"Front Aging Neurosci"},{"issue":"Suppl 1","key":"236_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/jnc.13731","volume":"139","author":"A Bose","year":"2016","unstructured":"Bose A, Beal MF. Mitochondrial dysfunction in Parkinson\u2019s disease. J Neurochem. 2016;139(Suppl 1):216\u201331.","journal-title":"J Neurochem"},{"issue":"2","key":"236_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00702-016-1616-4","volume":"124","author":"CJ Choong","year":"2017","unstructured":"Choong CJ, Mochizuki H. Gene therapy targeting mitochondrial pathway in Parkinson\u2019s disease. J Neural Transm (Vienna). 2017;124(2):193\u2013207.","journal-title":"J Neural Transm (Vienna)"},{"key":"236_CR6","doi-asserted-by":"crossref","unstructured":"Drouin-Ouellet J. Mitochondrial complex I deficiency and Parkinson disease. Nat Rev Neurosci. 2023.","DOI":"10.1038\/s41583-023-00676-y"},{"issue":"1","key":"236_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41392-022-00983-3","volume":"7","author":"M Vos","year":"2022","unstructured":"Vos M. Mitochondrial complex I deficiency: guilty in Parkinson\u2019s disease. Signal Transduct Target Ther. 2022;7(1):136.","journal-title":"Signal Transduct Target Ther"},{"issue":"7886","key":"236_CR8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41586-021-04059-0","volume":"599","author":"P Gonzalez-Rodriguez","year":"2021","unstructured":"Gonzalez-Rodriguez P, Zampese E, Stout KA, Guzman JN, Ilijic E, Yang B, et al. Disruption of mitochondrial complex I induces progressive parkinsonism. Nature. 2021;599(7886):650\u20136.","journal-title":"Nature"},{"issue":"7\u20138","key":"236_CR9","first-page":"865","volume":"380","author":"S K\u00f6sel","year":"1999","unstructured":"K\u00f6sel S, Hofhaus G, Maassen A, Vieregge P, Graeber MB. Role of mitochondria in Parkinson disease. Biol Chem. 1999;380(7\u20138):865\u201370.","journal-title":"Biol Chem"},{"key":"236_CR10","doi-asserted-by":"crossref","unstructured":"Prasuhn J, Bruggemann N. Gene Therapeutic Approaches for the Treatment of Mitochondrial Dysfunction in Parkinson\u2019s Disease. Genes (Basel). 2021;12(11).","DOI":"10.3390\/genes12111840"},{"issue":"4587","key":"236_CR11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1126\/science.6823561","volume":"219","author":"JW Langston","year":"1983","unstructured":"Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219(4587):979\u201380.","journal-title":"Science"},{"issue":"1","key":"236_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3233\/NRE-171450","volume":"40","author":"Top 25 NeuroRehabilitation articles","year":"2017","unstructured":"Top 25 NeuroRehabilitation articles. NeuroRehabilitation. 2017;40(1):9\u201310.","journal-title":"NeuroRehabilitation"},{"key":"236_CR13","doi-asserted-by":"crossref","unstructured":"San Miguel M, Martin KL, Stone J, Johnstone DM. Photobiomodulation mitigates Cerebrovascular Leakage Induced by the Parkinsonian Neurotoxin MPTP. Biomolecules. 2019;9(10).","DOI":"10.3390\/biom9100564"},{"key":"236_CR14","doi-asserted-by":"publisher","first-page":"101263","DOI":"10.1016\/j.arr.2021.101263","volume":"67","author":"PA Dionisio","year":"2021","unstructured":"Dionisio PA, Amaral JD, Rodrigues CMP. Oxidative stress and regulated cell death in Parkinson\u2019s disease. Ageing Res Rev. 2021;67:101263.","journal-title":"Ageing Res Rev"},{"issue":"3","key":"236_CR15","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1172\/JCI64264","volume":"123","author":"AF Santidrian","year":"2013","unstructured":"Santidrian AF, Matsuno-Yagi A, Ritland M, Seo BB, LeBoeuf SE, Gay LJ, et al. Mitochondrial complex I activity and NAD+\/NADH balance regulate breast cancer progression. J Clin Invest. 2013;123(3):1068\u201381.","journal-title":"J Clin Invest"},{"issue":"6","key":"236_CR16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.devcel.2017.02.020","volume":"40","author":"EA Bordt","year":"2017","unstructured":"Bordt EA, Clerc P, Roelofs BA, Saladino AJ, Tretter L, Adam-Vizi V, et al. The putative Drp1 inhibitor mdivi-1 is a reversible mitochondrial complex I inhibitor that modulates reactive oxygen species. Dev Cell. 2017;40(6):583\u2013e946.","journal-title":"Dev Cell"},{"issue":"7\u20138","key":"236_CR17","doi-asserted-by":"publisher","first-page":"e3027","DOI":"10.1002\/jgm.3027","volume":"20","author":"W Yuan","year":"2018","unstructured":"Yuan W, Chen J, Cao Y, Yang L, Shen L, Bian Q, et al. Comparative analysis and optimization of protocols for producing recombinant lentivirus carrying the anti-Her2 chimeric antigen receptor gene. J Gene Med. 2018;20(7\u20138):e3027.","journal-title":"J Gene Med"},{"key":"236_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.nbd.2015.09.009","volume":"82","author":"EM Rocha","year":"2015","unstructured":"Rocha EM, Smith GA, Park E, Cao H, Brown E, Hayes MA, et al. Glucocerebrosidase gene therapy prevents alpha-synucleinopathy of midbrain dopamine neurons. Neurobiol Dis. 2015;82:495\u2013503.","journal-title":"Neurobiol Dis"},{"issue":"42","key":"236_CR19","doi-asserted-by":"publisher","first-page":"14592","DOI":"10.1523\/JNEUROSCI.0539-12.2012","volume":"32","author":"JM Morganti","year":"2012","unstructured":"Morganti JM, Nash KR, Grimmig BA, Ranjit S, Small B, Bickford PC, et al. The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson\u2019s disease. J Neurosci. 2012;32(42):14592\u2013601.","journal-title":"J Neurosci"},{"key":"236_CR20","doi-asserted-by":"crossref","unstructured":"Zhang J, Sun B, Yang J, Chen Z, Li Z, Zhang N et al. Comparison of the effect of rotenone and 1\u2013methyl\u20134\u2013phenyl\u20131,2,3,6\u2013tetrahydropyridine on inducing chronic Parkinson\u2019s disease in mouse models. Mol Med Rep. 2022;25(3).","DOI":"10.3892\/mmr.2022.12607"},{"key":"236_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.neuro.2018.12.009","volume":"71","author":"S Bhurtel","year":"2019","unstructured":"Bhurtel S, Katila N, Srivastav S, Neupane S, Choi DY. Mechanistic comparison between MPTP and rotenone neurotoxicity in mice. Neurotoxicology. 2019;71:113\u201321.","journal-title":"Neurotoxicology"},{"issue":"2","key":"236_CR22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s12035-019-01744-0","volume":"57","author":"D Balke","year":"2020","unstructured":"Balke D, Tatenhorst L, Dambeck V, Ribas VT, Vahsen BF, Michel U, et al. AAV-Mediated expression of Dominant-negative ULK1 increases neuronal survival and enhances Motor Performance in the MPTP Mouse Model of Parkinson\u2019s Disease. Mol Neurobiol. 2020;57(2):685\u201397.","journal-title":"Mol Neurobiol"},{"key":"236_CR23","doi-asserted-by":"crossref","unstructured":"Shen J, Zha Q, Yang QH, Zhou YQ, Liang X, Chen YJ et al. Inhibiting Von Hippel\u2013Lindau protein-mediated dishevelled ubiquitination protects against experimental parkinsonism. Acta Pharmacol Sin. 2022.","DOI":"10.1038\/s41401-022-01014-1"},{"issue":"17","key":"236_CR24","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1523\/JNEUROSCI.2952-16.2017","volume":"37","author":"I Tesseur","year":"2017","unstructured":"Tesseur I, Nguyen A, Chang B, Li L, Woodling NS, Wyss-Coray T, et al. Deficiency in neuronal TGF-beta signaling leads to Nigrostriatal Degeneration and activation of TGF-beta signaling protects against MPTP Neurotoxicity in mice. J Neurosci. 2017;37(17):4584\u201392.","journal-title":"J Neurosci"},{"key":"236_CR25","first-page":"438370","volume":"2011","author":"J Barber-Singh","year":"2010","unstructured":"Barber-Singh J, Seo BB, Matsuno-Yagi A, Yagi T. Protective role of rAAV-NDI1, serotype 5, in an Acute MPTP Mouse Parkinson\u2019s model. Parkinsons Dis. 2010;2011:438370.","journal-title":"Parkinsons Dis"},{"issue":"4","key":"236_CR26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1089\/rej.2009.0854","volume":"12","author":"J Barber-Singh","year":"2009","unstructured":"Barber-Singh J, Seo BB, Nakamaru-Ogiso E, Lau YS, Matsuno-Yagi A, Yagi T. Neuroprotective effect of long-term NDI1 gene expression in a chronic mouse model of Parkinson disorder. Rejuvenation Res. 2009;12(4):259\u201367.","journal-title":"Rejuvenation Res"},{"issue":"20","key":"236_CR27","doi-asserted-by":"publisher","first-page":"14250","DOI":"10.1074\/jbc.M600922200","volume":"281","author":"BB Seo","year":"2006","unstructured":"Seo BB, Nakamaru-Ogiso E, Flotte TR, Matsuno-Yagi A, Yagi T. In vivo complementation of complex I by the yeast Ndi1 enzyme. Possible application for treatment of Parkinson disease. J Biol Chem. 2006;281(20):14250\u20135.","journal-title":"J Biol Chem"},{"issue":"1","key":"236_CR28","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1212\/WNL.0000000000012952","volume":"98","author":"CW Christine","year":"2022","unstructured":"Christine CW, Richardson RM, Van Laar AD, Thompson ME, Fine EM, Khwaja OS, et al. Safety of AADC Gene Therapy for moderately Advanced Parkinson Disease: three-year outcomes from the PD-1101 Trial. Neurology. 2022;98(1):e40\u201350.","journal-title":"Neurology"},{"issue":"14","key":"236_CR29","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1089\/scd.2018.0030","volume":"27","author":"G Ge","year":"2018","unstructured":"Ge G, Chen C, Guderyon MJ, Liu J, He Z, Yu Y, et al. Regulatable Lentiviral hematopoietic stem cell gene therapy in a mouse model of Parkinson\u2019s Disease. Stem Cells Dev. 2018;27(14):995\u20131005.","journal-title":"Stem Cells Dev"},{"issue":"8","key":"236_CR30","doi-asserted-by":"publisher","first-page":"13762","DOI":"10.1002\/jcp.28055","volume":"234","author":"MF Mu\u00f1oz","year":"2019","unstructured":"Mu\u00f1oz MF, Arg\u00fcelles S, Medina R, Cano M, Ayala A. Adipose-derived stem cells decreased microglia activation and protected dopaminergic loss in rat lipopolysaccharide model. J Cell Physiol. 2019;234(8):13762\u201372.","journal-title":"J Cell Physiol"},{"issue":"4","key":"236_CR31","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s13311-020-00940-4","volume":"17","author":"PC Buttery","year":"2020","unstructured":"Buttery PC, Barker RA. Gene and cell-based therapies for Parkinson\u2019s Disease. Where Are We? Neurother. 2020;17(4):1539\u201362.","journal-title":"Where Are We? Neurother"},{"issue":"7","key":"236_CR32","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1007\/s12035-018-1419-8","volume":"56","author":"K Jamebozorgi","year":"2019","unstructured":"Jamebozorgi K, Taghizadeh E, Rostami D, Pormasoumi H, Barreto GE, Hayat SMG, et al. Cellular and Molecular aspects of Parkinson Treatment: future therapeutic perspectives. Mol Neurobiol. 2019;56(7):4799\u2013811.","journal-title":"Mol Neurobiol"},{"key":"236_CR33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3389\/fnagi.2017.00126","volume":"9","author":"JY Lin","year":"2017","unstructured":"Lin JY, Xie CL, Zhang SF, Yuan W, Liu ZG. Current experimental studies of Gene Therapy in Parkinson\u2019s Disease. Front Aging Neurosci. 2017;9:126.","journal-title":"Front Aging Neurosci"},{"key":"236_CR34","doi-asserted-by":"publisher","first-page":"986668","DOI":"10.3389\/fphar.2022.986668","volume":"13","author":"SK Pandey","year":"2022","unstructured":"Pandey SK, Singh RK. Recent developments in nucleic acid-based therapies for Parkinson\u2019s disease: current status, clinical potential, and future strategies. Front Pharmacol. 2022;13:986668.","journal-title":"Front Pharmacol"},{"issue":"4","key":"236_CR35","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/14737175.2022.2056446","volume":"22","author":"SO El Ganainy","year":"2022","unstructured":"El Ganainy SO, Cijsouw T, Ali MA, Schoch S, Hanafy AS. Stereotaxic-assisted gene therapy in Alzheimer\u2019s and Parkinson\u2019s diseases: therapeutic potentials and clinical frontiers. Expert Rev Neurother. 2022;22(4):319\u201335.","journal-title":"Expert Rev Neurother"},{"key":"236_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fnana.2016.00123","volume":"10","author":"P Vald\u00e9s","year":"2016","unstructured":"Vald\u00e9s P, Schneider BL. Gene therapy: a Promising Approach for Neuroprotection in Parkinson\u2019s Disease? Front Neuroanat. 2016;10:123.","journal-title":"Front Neuroanat"},{"key":"236_CR37","doi-asserted-by":"crossref","unstructured":"Nam Y, Moon GJ, Kim SR. Therapeutic potential of AAV1-Rheb(S16H) transduction against neurodegenerative diseases. Int J Mol Sci. 2021;22(6).","DOI":"10.3390\/ijms22063064"},{"issue":"5","key":"236_CR38","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.25450","volume":"85","author":"CW Christine","year":"2019","unstructured":"Christine CW, Bankiewicz KS, Van Laar AD, Richardson RM, Ravina B, Kells AP, et al. Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson\u2019s disease. Ann Neurol. 2019;85(5):704\u201314.","journal-title":"Ann Neurol"},{"issue":"2","key":"236_CR39","doi-asserted-by":"publisher","first-page":"e0169965","DOI":"10.1371\/journal.pone.0169965","volume":"12","author":"A Ciesielska","year":"2017","unstructured":"Ciesielska A, Samaranch L, San Sebastian W, Dickson DW, Goldman S, Forsayeth J, et al. Depletion of AADC activity in caudate nucleus and putamen of Parkinson\u2019s disease patients; implications for ongoing AAV2-AADC gene therapy trial. PLoS ONE. 2017;12(2):e0169965.","journal-title":"PLoS ONE"},{"issue":"s2","key":"236_CR40","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.3233\/JPD-212724","volume":"11","author":"AD Van Laar","year":"2021","unstructured":"Van Laar AD, Van Laar VS, San Sebastian W, Merola A, Elder JB, Lonser RR, et al. An update on Gene Therapy approaches for Parkinson\u2019s Disease: restoration of dopaminergic function. J Parkinsons Dis. 2021;11(s2):S173\u201382.","journal-title":"J Parkinsons Dis"},{"issue":"7","key":"236_CR41","doi-asserted-by":"publisher","first-page":"e90133","DOI":"10.1172\/jci.insight.90133","volume":"2","author":"M Niethammer","year":"2017","unstructured":"Niethammer M, Tang CC, LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, et al. Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson\u2019s disease. JCI Insight. 2017;2(7):e90133.","journal-title":"JCI Insight"},{"issue":"12","key":"236_CR42","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1016\/j.ymthe.2022.08.003","volume":"30","author":"MT Rocco","year":"2022","unstructured":"Rocco MT, Akhter AS, Ehrlich DJ, Scott GC, Lungu C, Munjal V, et al. Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson\u2019s disease. Mol Ther. 2022;30(12):3632\u20138.","journal-title":"Mol Ther"},{"issue":"4","key":"236_CR43","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/hum.2011.220","volume":"23","author":"G Mittermeyer","year":"2012","unstructured":"Mittermeyer G, Christine CW, Rosenbluth KH, Baker SL, Starr P, Larson P, et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson\u2019s disease. Hum Gene Ther. 2012;23(4):377\u201381.","journal-title":"Hum Gene Ther"},{"issue":"7","key":"236_CR44","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1089\/hum.2015.134","volume":"27","author":"WJ Marks Jr","year":"2016","unstructured":"Marks WJ Jr., Baumann TL, Bartus RT. Long-term safety of patients with Parkinson\u2019s Disease receiving rAAV2-Neurturin (CERE-120) gene transfer. Hum Gene Ther. 2016;27(7):522\u20137.","journal-title":"Hum Gene Ther"},{"key":"236_CR45","first-page":"128","volume":"10","author":"B Blits","year":"2016","unstructured":"Blits B, Petry H. Perspective on the Road toward Gene Therapy for Parkinson\u2019s Disease. Front Neuroanat. 2016;10:128.","journal-title":"Front Neuroanat"},{"issue":"4","key":"236_CR46","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3233\/JPD-229002","volume":"12","author":"K McFarthing","year":"2022","unstructured":"McFarthing K, Rafaloff G, Baptista M, Mursaleen L, Fuest R, Wyse RK, et al. Parkinson\u2019s Disease Drug therapies in the clinical Trial Pipeline: 2022 update. J Parkinsons Dis. 2022;12(4):1073\u201382.","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"236_CR47","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3233\/JPD-219006","volume":"11","author":"K McFarthing","year":"2021","unstructured":"McFarthing K, Rafaloff G, Baptista MAS, Wyse RK, Stott SRW. Parkinson\u2019s Disease Drug therapies in the clinical Trial Pipeline: 2021 update. J Parkinsons Dis. 2021;11(3):891\u2013903.","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"236_CR48","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3233\/JPD-202128","volume":"10","author":"K McFarthing","year":"2020","unstructured":"McFarthing K, Buff S, Rafaloff G, Dominey T, Wyse RK, Stott SRW. Parkinson\u2019s Disease Drug therapies in the clinical Trial Pipeline: 2020. J Parkinsons Dis. 2020;10(3):757\u201374.","journal-title":"J Parkinsons Dis"},{"issue":"12","key":"236_CR49","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.jcyt.2013.06.008","volume":"15","author":"JC Chang","year":"2013","unstructured":"Chang JC, Liu KH, Chuang CS, Su HL, Wei YH, Kuo SJ, et al. Treatment of human cells derived from MERRF syndrome by peptide-mediated mitochondrial delivery. Cytotherapy. 2013;15(12):1580\u201396.","journal-title":"Cytotherapy"},{"issue":"4","key":"236_CR50","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10863-014-9559-7","volume":"46","author":"S Pepe","year":"2014","unstructured":"Pepe S, Mentzer RM Jr., Gottlieb RA. Cell-permeable protein therapy for complex I dysfunction. J Bioenerg Biomembr. 2014;46(4):337\u201345.","journal-title":"J Bioenerg Biomembr"},{"issue":"20","key":"236_CR51","doi-asserted-by":"publisher","first-page":"E1238","DOI":"10.1073\/pnas.1119577109","volume":"109","author":"H Yu","year":"2012","unstructured":"Yu H, Koilkonda RD, Chou TH, Porciatti V, Ozdemir SS, Chiodo V, et al. Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber\u2019s hereditary optic neuropathy in a mouse model. Proc Natl Acad Sci U S A. 2012;109(20):E1238\u201347.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"236_CR52","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jamaophthalmol.2013.7630","volume":"132","author":"RD Koilkonda","year":"2014","unstructured":"Koilkonda RD, Yu H, Chou TH, Feuer WJ, Ruggeri M, Porciatti V, et al. Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial. JAMA Ophthalmol. 2014;132(4):409\u201320.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"236_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/brain\/awab426","volume":"145","author":"MAE van de Wal","year":"2022","unstructured":"van de Wal MAE, Adjobo-Hermans MJW, Keijer J, Schirris TJJ, Homberg JR, Wieckowski MR, et al. Ndufs4 knockout mouse models of Leigh syndrome: pathophysiology and intervention. Brain. 2022;145(1):45\u201363.","journal-title":"Brain"},{"issue":"10","key":"236_CR54","doi-asserted-by":"publisher","first-page":"e25910","DOI":"10.1371\/journal.pone.0025910","volume":"6","author":"M Marella","year":"2011","unstructured":"Marella M, Seo BB, Flotte TR, Matsuno-Yagi A, Yagi T. No immune responses by the expression of the yeast Ndi1 protein in rats. PLoS ONE. 2011;6(10):e25910.","journal-title":"PLoS ONE"},{"issue":"11","key":"236_CR55","doi-asserted-by":"publisher","first-page":"e50644","DOI":"10.1371\/journal.pone.0050644","volume":"7","author":"J Cho","year":"2012","unstructured":"Cho J, Hur JH, Graniel J, Benzer S, Walker DW. Expression of yeast NDI1 rescues a Drosophila complex I assembly defect. PLoS ONE. 2012;7(11):e50644.","journal-title":"PLoS ONE"},{"issue":"3","key":"236_CR56","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1074248413515750","volume":"19","author":"RM Mentzer Jr","year":"2014","unstructured":"Mentzer RM Jr., Wider J, Perry CN, Gottlieb RA. Reduction of infarct size by the therapeutic protein TAT-Ndi1 in vivo. J Cardiovasc Pharmacol Ther. 2014;19(3):315\u201320.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"5","key":"236_CR57","first-page":"579","volume":"97","author":"M Forte","year":"2019","unstructured":"Forte M, Palmerio S, Bianchi F, Volpe M, Rubattu S. Mitochondrial complex I deficiency and cardiovascular diseases: current evidence and future directions. J Mol Med (Berl). 2019;97(5):579\u201391.","journal-title":"J Mol Med (Berl)"},{"issue":"4","key":"236_CR58","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1007\/s12035-019-01857-6","volume":"57","author":"V Talla","year":"2020","unstructured":"Talla V, Koilkonda R, Guy J. Gene Therapy with single-subunit yeast NADH-Ubiquinone oxidoreductase (NDI1) improves the visual function in experimental autoimmune encephalomyelitis (EAE) mice model of multiple sclerosis (MS). Mol Neurobiol. 2020;57(4):1952\u201365.","journal-title":"Mol Neurobiol"},{"key":"236_CR59","doi-asserted-by":"publisher","first-page":"101606","DOI":"10.1016\/j.redox.2020.101606","volume":"36","author":"AR Chowdhury","year":"2020","unstructured":"Chowdhury AR, Zielonka J, Kalyanaraman B, Hartley RC, Murphy MP, Avadhani NG. Mitochondria-targeted paraquat and metformin mediate ROS production to induce multiple pathways of retrograde signaling: a dose-dependent phenomenon. Redox Biol. 2020;36:101606.","journal-title":"Redox Biol"},{"issue":"4","key":"236_CR60","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1074\/jbc.M708597200","volume":"283","author":"HM Cocheme","year":"2008","unstructured":"Cocheme HM, Murphy MP. Complex I is the major site of mitochondrial superoxide production by paraquat. J Biol Chem. 2008;283(4):1786\u201398.","journal-title":"J Biol Chem"},{"issue":"7","key":"236_CR61","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/cdd.2009.217","volume":"17","author":"C Berry","year":"2010","unstructured":"Berry C, La Vecchia C, Nicotera P. Paraquat and Parkinson\u2019s disease. Cell Death Differ. 2010;17(7):1115\u201325.","journal-title":"Cell Death Differ"},{"issue":"5","key":"236_CR62","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/labinvest.2015.161","volume":"96","author":"XF Zhang","year":"2016","unstructured":"Zhang XF, Thompson M, Xu YH. Multifactorial theory applied to the neurotoxicity of paraquat and paraquat-induced mechanisms of developing Parkinson\u2019s disease. Lab Invest. 2016;96(5):496\u2013507.","journal-title":"Lab Invest"}],"container-title":["Biological Procedures Online"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12575-024-00236-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12575-024-00236-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12575-024-00236-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T03:02:35Z","timestamp":1712631755000},"score":1,"resource":{"primary":{"URL":"https:\/\/biologicalproceduresonline.biomedcentral.com\/articles\/10.1186\/s12575-024-00236-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["236"],"URL":"https:\/\/doi.org\/10.1186\/s12575-024-00236-3","relation":{},"ISSN":["1480-9222"],"issn-type":[{"value":"1480-9222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]},"assertion":[{"value":"16 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study conducted according to the guidelines of Declaration of Helsinki, and approved by the Ethics Committee of Wenzhou Medical University in Wenzhou, China (wydw2020-0804).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9"}}